In the BioHarmony Drug Report Database

"Preview" Icon

Ofatumumab

Arzerra, Kesimpta (ofatumumab) is an antibody pharmaceutical. Ofatumumab was first approved as Arzerra on 2009-10-26. It is used to treat lymphoid leukemia in the USA. It has been approved in Europe to treat relapsing-remitting multiple sclerosis. The pharmaceutical is active against B-lymphocyte antigen CD20.

 

Trade Name

 

Kesimpta
 

Common Name

 

ofatumumab
 

ChEMBL ID

 

CHEMBL1201836
 

Indication

 

lymphoid leukemia, relapsing-remitting multiple sclerosis
 

Drug Class

 

Monoclonal antibodies

Image (chem structure or protein)

Ofatumumab structure rendering